| Literature DB >> 33413496 |
Ming Yi1, Mengke Niu1,2, Linping Xu2, Suxia Luo3, Kongming Wu4,5.
Abstract
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and eradicate cancer cells. However, only a subset of PD-L1 positive patients benefits from α-PD-1/PD-L1 therapies. Actually, PD-L1 expression is regulated by various factors, leading to the diverse significances of PD-L1 positivity. Understanding the mechanisms of PD-L1 regulation is helpful to select patients and enhance the treatment effect. In this review, we focused on PD-L1 regulators at the levels of transcription, post-transcription, post-translation. Besides, we discussed the potential applications of these laboratory findings in the clinic.Entities:
Keywords: Cancer immunology; PD-1; PD-L1; Post-transcriptional modification; Transcriptional regulation
Year: 2021 PMID: 33413496 PMCID: PMC7792099 DOI: 10.1186/s13045-020-01027-5
Source DB: PubMed Journal: J Hematol Oncol ISSN: 1756-8722 Impact factor: 17.388